The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2
Autophagy
Breast cancer
CHD4
ERBB2
Trastuzumab
Journal
Biology open
ISSN: 2046-6390
Titre abrégé: Biol Open
Pays: England
ID NLM: 101578018
Informations de publication
Date de publication:
18 Apr 2019
18 Apr 2019
Historique:
pubmed:
11
4
2019
medline:
11
4
2019
entrez:
11
4
2019
Statut:
epublish
Résumé
The chromodomain helicase DNA-binding 4 (CHD4), a member of the nucleosome remodeling and deacetylases (NuRD) complex, has been identified as an oncogene that modulates proliferation and migration of breast cancers (BC). ERBB2 is an oncogenic driver in 20-30% of BC in which its overexpression leads to increased chemoresistance. Here we investigated whether CHD4 depletion affects the ERBB2 cascade and autophagy, which represents a mechanism of resistance against Trastuzumab (Tz), a therapeutic anti-ERBB2 antibody. We show that CHD4 depletion in two ERBB2
Identifiants
pubmed: 30967373
pii: bio.038323
doi: 10.1242/bio.038323
pmc: PMC6504000
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2019. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing or financial interests.
Références
Oncogene. 2000 Dec 11;19(53):6102-14
pubmed: 11156523
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Oncology. 2001;61 Suppl 2:1-13
pubmed: 11694782
Cancer Res. 2002 Jul 15;62(14):4132-41
pubmed: 12124352
Cell Cycle. 2005 Jan;4(1):87-95
pubmed: 15611642
Oncogene. 2005 Apr 21;24(18):3002-10
pubmed: 15735715
Cancer Lett. 2006 Feb 8;232(2):123-38
pubmed: 16458110
Methods Enzymol. 2009;452:181-97
pubmed: 19200883
PLoS One. 2009 Jul 16;4(7):e6251
pubmed: 19606230
Endocr Relat Cancer. 2010 Jan 29;17(1):7-16
pubmed: 19776290
Clin Cancer Res. 2011 Feb 15;17(4):654-66
pubmed: 21325294
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
J Clin Invest. 2011 Oct;121(10):3786-8
pubmed: 21965334
Curr Protoc Cell Biol. 2012 Mar;Chapter 15:Unit 15.16
pubmed: 22422474
Front Oncol. 2012 Jun 18;2:62
pubmed: 22720269
Curr Pharm Des. 2013;19(3):347-65
pubmed: 22920906
Biochem Soc Trans. 2013 Jun;41(3):777-82
pubmed: 23697937
Oncogene. 2014 Apr 24;33(17):2157-68
pubmed: 23708667
Cell Stem Cell. 2013 Nov 7;13(5):617-25
pubmed: 24209762
PLoS One. 2014 Jan 31;9(1):e86847
pubmed: 24497985
Cancer Biol Ther. 2014 Aug;15(8):1029-41
pubmed: 24835103
Membranes (Basel). 2014 Aug 06;4(3):424-46
pubmed: 25102001
BMC Med. 2014 Aug 12;12:132
pubmed: 25285786
J Hepatol. 2015 Nov;63(5):1164-72
pubmed: 26095183
Blood. 2015 Sep 17;126(12):1462-72
pubmed: 26265695
Tumour Biol. 2016 Feb;37(2):2321-31
pubmed: 26369543
Pharmacol Ther. 2016 Feb;158:63-70
pubmed: 26645663
Autophagy. 2015;11(12):2309-22
pubmed: 26735435
Cell Metab. 2016 May 10;23(5):881-92
pubmed: 27166947
Oncotarget. 2016 Dec 6;7(49):80901-80915
pubmed: 27779108
J Cell Sci. 2016 Dec 1;129(23):4329-4339
pubmed: 27799357
Oncotarget. 2016 Dec 20;7(51):85411-85429
pubmed: 27863425
Mol Cell. 2017 Mar 2;65(5):781-785
pubmed: 28257699
Microb Cell. 2016 Dec 01;3(12):588-596
pubmed: 28357331
Cancer Cell. 2017 May 8;31(5):653-668.e7
pubmed: 28486105
Int J Mol Sci. 2017 Jul 11;18(7):null
pubmed: 28696368
Oncotarget. 2017 May 8;8(36):60109-60122
pubmed: 28947957
J Exp Clin Cancer Res. 2017 Nov 3;36(1):154
pubmed: 29100552
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Dis Markers. 2017;2017:7849108
pubmed: 29403144
Cell Death Dis. 2018 Feb 7;9(2):177
pubmed: 29415996
Cell Death Dis. 2018 Feb 7;9(2):166
pubmed: 29416016
Diseases. 2018 Apr 10;6(2):null
pubmed: 29642647
J Neurochem. 2018 Oct;147(1):99-109
pubmed: 29953622